Although in diffuse cutaneous subgroup, the sensitivity was >96 for both criteria, in limited cutaneous subgroup, the sensitivity was preserved for ACR/EULAR(2013) while apparently decreased for ACR(1980) criteria (<70). The sensitivity for both of the two sets were lowest in the sclerodermic group. In SSC patients with limited or no skin involvement, non-skin manifestations, NVC findings and specific serology should be carefully sought. Some of these patients could not be classified by the current criteria.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.6000

THURSDAY, 04 JUNE 2020

Spondyloarthritis - treatment

THU0370

CLUSTER-RANDOMIZED PRAGMATIC CLINICAL TRIAL EVALUATING THE POTENTIAL BENEFIT OF A TIGHT-CONTROL AND TREAT-TO-TARGET STRATEGY IN AXIAL SPONDYLOARTHRITIS: THE RESULTS OF THE TICOSPA TRIAL.

A. Moltó¹, C. López-Medina¹, F. Van den Bosch¹, A. Boonen¹, C. Webers¹, E. Dernis¹, F. A. Van Gaalen¹, M. Soubrier¹, P. Claudepierre¹, A. Baillet¹, M. Starmans-Kool¹, D. Van der Heijde¹, M. Dougados¹. ¹TICOSPA Study Group, Paris, France

Background: Current recommendations for axial spondyloarthritis (axSpA) management include tight control and treat-to-target (TC) strategies, but no study has evaluated its potential benefit.

Objectives: To evaluate the benefit of TC strategies in comparison to usual care (UC) in patients with axSpA.

Methods: *Study design:* Pragmatic, prospective, cluster-randomized controlled (2 arms), one-year trial (NCT03043846). *Centers:* 18 axSpA expert centers randomly allocated (1:1) to the treatment arm: TC vs. UC. *Patients:* axSpA diagnosis and ASAS criteria, non-optimally treated with NSAIDs, bDMARD-naïve, and ASDAS > 2.1 at inclusion. *Study treatment:* a) TC arm: the strategy was pre-specified by the scientific committee based on current axSpA recommendations and aiming at a target (ASDAS <2.1); visits every 4w; b) UC arm: treatment decisions were at the rheumatologist's discretion with visits every 12w. *Outcomes:* the % of patients with a significant (>30%) improvement in the ASDAS-HI score over one-year follow-up was the main outcome. Other outcomes (disease activity, quality of life, treatment, ...) over follow-up were evaluated (Table 1). The number/type of adverse events were collected. *Statistical analysis:* this was an intention-to-treat analysis. To take into account the cluster-randomization design, for all outcomes, two models were performed: first a two-level mixed model with 2 random effects was used to estimate the % of responders/the change of the outcome over follow-up (i.e. mod1); in a second step, the imbalanced variables observed at baseline were included in the model (i.e.mod2). Cost-effectiveness was assessed by estimating the (baseline- and cluster-adjusted) incremental cost per quality-adjusted life-year (QALY) gained for TC vs. UC.

	Estimated outcomes at week 48		Cluster-adjusted (mod1)	Cluster and imbalance-adjusted (mod2)
	TC	UC		
ASDAS LDA*	76.5%	59.5%	<0.01	0.03
ASDAS ID	25.9%	18.7%	-	-
ASDAS CII	61.2%	46.0%	<0.01	0.02
ASDAS MI	16.5%	14.9%	-	-
ASAS40	52.3%	34.7%	<0.01	0.01
ASAS20	94.9%	85.9%	<0.01	0.03
BASDAI 50	79.0%	43.8%	0.01	0.03
Physician Global (0-10)	2.0 (0.2)	1.8 (0.2)	-	-
CRP (mg/L)	3.9 (1.4)	3.5 (1.5)	-	-
BASG (0-10)	2.6 (0.5)	3.4 (0.5)	0.09	-
BASFI (0-10)	1.7 (0.5)	2.4 (0.5)	-	-
ASAS HI SMD	47.3%	36.1%	-	-
EQ5D	0.7 (0.1)	0.8 (0.1)	0.02	-
ASAS-NSAID score	1.5 (2.2)	- 4.9 (2.9)	-	-

Results: 160 patients were included (80 in TC and 80 in UC). Mean age was 37.9(11.0) years with a disease duration of 3.7(6.2) years, 51.2% were males. A radiographic damage of the SI-joints, a (ever) positive MRI sacroiliitis and HLA-B27+ were seen in 46.9%, 81.9% and 75.0% patients respectively. Mean ASDAS at inclusion was 3.0 (0.7) and mean ASASHI was 8.6 (3.7). 72 patients per group attended the one-year visit. Although 47.3% vs. 36.1% patients in the TC and UC arms achieved a significant improvement in ASASHI at the one-year visit, the difference was not statistically significant, with either model. Across all other

outcomes a trend was observed in favor of the TC arm (Table 1). The number of bDMARDs was significantly higher in TC arm (56.2% vs. 27.2%). The number of infections was comparable in both groups (15 vs. 16 in the TC and UC, respectively), with only 2 severe infections occurring in the UC arm. From a societal perspective, TC resulted in an additional 0.04 QALY and saved €265 when compared to UC and a 67% probability of being cost-effective at a cost-effectiveness threshold of €20,000 per QALY.

Conclusion: In this setting of SpA expert centers, UC resulted in a good outcome in a substantial number of patients but the TC was not superior for the primary outcome despite a greater number of bDMARDs prescription. Nevertheless, a general trend in favor of the tight control was observed, with a comparable safety profile and was found to be favorable from a societal health economic perspective.

Acknowledgments: this trial has been conducted thanks to an unrestricted grant from UCB

Disclosure of Interests: Anna Moltó Grant/research support from: Pfizer, UCB, Consultant of: Abbvie, BMS, MSD, Novartis, Pfizer, UCB, Clementina López-Medina: None declared, Filip van den Bosch Consultant of: AbbVie, Celgene Corporation, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer, and UCB, Speakers bureau: AbbVie, Celgene Corporation, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer, and UCB, Annelies Boonen Grant/research support from: AbbVie, Consultant of: Galapagos, Lilly (all paid to the department), Casper Webers: None declared, Emmanuelle Dernis Speakers bureau: Lilly, Novartis, Floris A. van Gaalen: None declared, Martin SOUBRIER: None declared, Pascal Claudepierre Speakers bureau: Janssen, Novartis, Lilly, Athan Baillet Consultant of: Athan BAILLET has received honorarium fees from Abbvie for his participation as the coordinator of the systematic literature review, Miriam Starmans-Kool: None declared, Désirée van der Heijde Consultant of: AbbVie, Amgen, Astellas, Astra-Zeneca, BMS, Boehringer Ingelheim, Celgene, Cytone, Daiichi, Eisai, Eli-Lilly, Galapagos, Gilead Sciences, Inc., Glaxo-Smith-Kline, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, UCB Pharma; Director of Imaging Rheumatology BV, Maxime Dougados Grant/research support from: AbbVie, Eli Lilly, Merck, Novartis, Pfizer and UCB Pharma, Consultant of: AbbVie, Eli Lilly, Merck, Novartis, Pfizer and UCB Pharma, Speakers bureau: AbbVie, Eli Lilly, Merck, Novartis, Pfizer and UCB Pharma

DOI: 10.1136/annrheumdis-2020-eular.1543

THU0371

HIGH INTENSITY EXERCISE HAS COMPARABLE 3-MONTH EFFECTIVENESS TO TNF-INHIBITORS ON DISEASE ACTIVITY IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS. POST-HOC ANALYSES OF DATA FROM (THE ESPA TRIAL.)

S. Aarrestad Provan¹, E. Kristianslund², I. J. Berg², H. Solveig Dagfinrud¹, S. Halvorsen Sveaas¹. ¹Diakonhjemmet Hospital, National Resource Centre for Rehabilitation in Rheumatology, Oslo, Norway; ²Diakonhjemmet Hospital, Rheumatology, Oslo, Norway

Background: We have previously reported that a supervised 12-week high intensity cardiorespiratory and strengthening exercise programme reduced disease activity in patients with axial spondyloarthritis (axSpA), in an assessor blinded randomized controlled trial (ESPA)(1). There were no reports of disease flare, and the programme was deemed safe. It is of interest to compare the treatment response of the programme vs. the response to treatment with a biologic immune-modulating TNFalpha-inhibitor (TNFi).

Objectives: To compare 3-month change in disease activity following an exercise programme vs. treatment with a TNFi, in patients with axSpA.

Methods: Post-hoc comparison between participants in the intervention group in the ESPA and patients from NOR-DMARD, a longitudinal observational study, who commenced treatment with a TNFi (2). The inclusion criteria of ESPA were a diagnosis of axSpA, age 18-70 years and baseline BASDAI >3.5. Patients fulfilling these criteria were selected from NOR-DMARD. Data was collected at baseline and 3 months. The primary outcome was defined as ASDAS, and BASDAI scores, and secondary outcomes were BASDAI sub-scores and C-reactive protein (CRP). Baseline values were compared in bivariate analyses. Responses at 3 months were compared between the groups using ANCOVA models adjusted for age, gender and baseline values. The standardised mean difference in 3-month response between the exercise and TNFi groups was estimated by dividing the difference in change at 3-months by the standard deviation (SD) of change.

Results: Fifty patients were randomised to the exercise intervention in the ESPA study, mean age (SD) 45.2 (0.6), 25 males (50%). 344 patients in the NOR-DMARD study were eligible for the current analyses, mean age (SD) 39.6 (1.5), 150 males (43.6 %). Baseline demographics and estimated marginal means for disease activity at - months are presented in table 1. The standard mean differences are presented in Figure 1. There were no significant differences in change in disease activity at 3-months between patients participating in ESPA and patients starting a TNFi.

Table 1

	Baseline		3 months		Adjusted β for comparison at 3 months (95% CI)	p
Number	TNFi Mean(SE)	Exercise Mean(SE)	TNFi EMM (SE)	Exercise EMM(SE)		
Primary outcomes						
ASDAS	3.16 (0.05)	2.45 (0.12)	2.13 (0.06)	1.88 (0.15)	-0.25 (0.56,0.05)	0.11
BASDAI total	5.92 (0.08)	4.94 (0.22)	3.89 (0.12)	3.72 (0.32)	-0.18 (-0.85,0.50)	0.61
BASDAI subscores						
Fatigue	6.60 (0.11)	5.8 (0.25)	4.63 (0.14)	4.06 (0.39)	-0.57 (-1.39,0.25)	0.17
Pain	6.48 (0.11)	5.8 (0.27)	4.29 (0.15)	3.89 (0.39)	-0.39 (-1.21,0.42)	0.35
Peripheral arthritis	4.41 (0.15)	3.76 (0.31)	3.10 (0.13)	2.64 (0.35)	-0.45 (-1.18,0.29)	0.23
Enthesitis	5.41 (0.13)	4.46 (0.33)	3.54 (0.14)	3.30 (0.39)	-0.24 (-1.06,0.58)	0.57
Stiffness intensity	6.75 (0.11)	5.42 (0.30)	4.01 (0.14)	3.86 (0.37)	-0.16 (-0.95,0.63)	0.70
Stiffness duration	6.66 (0.15)	4.32 (0.35)	4.17 (0.15)	3.93 (0.41)	-0.24 (-1.11,0.63)	0.59
Soluble biomarker						
CRP	7.94 (0.72)	4.12 (0.71)	3.81 (0.38)	3.95 (0.95)	0.13 (-1.88, 2.15)	0.90

Adjusted β derived from ANCOVA models adjusted for age, gender and baseline values. Disease activity at 3 months was the dependent variable in the models. EMM: Estimated marginal means.

Figure 1 Standard mean difference in change in disease outcomes at 3 months

Conclusion: High intensity exercise has comparable 3-month effectiveness to TNF-inhibitors, in patients with axSpA. This confirms the important role of high-intensity exercise in the treatment of axSpA.

References:

- [1] Sveaas SH et al. High intensity exercise for 3 months reduces disease activity in axial spondyloarthritis (axSpA): a multicentre randomised trial of 100 patients. *Br J Sports Med*. 2019.
- [2] Kvien TK et al. A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases. *Clin Exp Rheumatol*. 2005;23(5 Suppl 39):S188-S94.

Disclosure of Interests: Sella Aarrestad Provan Consultant of: Novartis, Eirik kristianslund: None declared, Inger Jorid Berg: None declared, Hanne Solveig Dagfinrud: None declared, Silje Halvorsen Sveaas: None declared

DOI: 10.1136/annrheumdis-2020-eular.5821

THU0372

EFFECTIVENESS OF STEROID INJECTION FOR HAND PSORIATIC DACTYLITIS: RESULTS FROM A MULTICENTRE PROSPECTIVE OBSERVATIONAL STUDY.

N. Girolimetto¹, G. Citriniti¹, I. Tinazzi², P. Macchioni¹. ¹Unit of Rheumatology, Department of Rheumatology, Reggio Emilia, Italy; ²Unit of Rheumatology, Sacro Cuore Don Calabria Hospital, Negrar, Italy

Background: Dactylitis is a common feature of PsA, occurring in 16 to 49% of PsA patients, mostly in early disease.

Table 1. Variation of clinical parameters during follow up.

		T0 baseline	T1 1 month	T3 3 months	T0 vs T1 95% CI	T0 vs T3 95% CI
VAS - PAIN	LT	6.89±1.93	1.97±1.62	1.34±1.48	4.92 (4.17; 5.67)	5.55 (4.76; 6.32)
	ST	6.03±2.43	5.49±2.53	5.0±2.65	0.54 (-0.23;1.32)	1.03 (-0.02; 2.07)
	Mean differences (95% CI)	0.87 (-1.89; 0.16)	3.51 (2.53; 4.49)	3.66 (2.67; 4.65)		
VAS - FI	LT	7.87±1.53	2.76±1.87	1.68±1.54	5.11 (4.49; 5.72)	6.18 (5.52; 6.84)
	ST	6.89±1.92	6.14±2.25	5.74±2.63	0.74 (0.23; 1.26)	1.14 (0.32; 1.97)
	Mean differences (95%CI)	0.98 (-1.79; 0.17)	3.38 (2.42; 4.34)	4.05 (3.06; 5.05)		
Finger circumference (cm)	LT	7.17±0.57	6.61±0.59	6.55±0.54	0.56 (0.46; 0.65)	0.62 (0.52; 0.73)
	ST	7.05±0.80	6.90±0.89	6.88±0.91	0.15 (0.06; 0.25)	0.17 (0.07; 0.27)
	Mean differences (95%CI)	0.12 (-0.44; 0.21)	0.29 (-0.07- 0.69)	0.33 (-0.02 -0.68)		
LDI-b	LT	12.31±0.03	9.91±7.15	1.25±4.35	8.40 (5.73;11.06)	11.05 (8.22; 13.89)
	ST	14.97±11.07	9.88±10.98	10.04±11.09	5.10 (1.63; 8.55)	4.93 (1.54; 8.32)
	Mean differences (95%CI)	2.67 (-1.82; 7.16)	5.97 (1.58; 10.35)	8.79 (4.74;12.83)		

VAS, visual analogue scale; VAS-FI, Visual analogue scale for functional impairment; LDI-b, Leed's dactylitic index basic; LT, local treatment group; ST, systemic treatment group.

Objectives: To assess the effectiveness of steroid injection (local treatment, LT) into the digital flexor tendon sheath for the treatment of active dactylitis in PsA patients as compared to systemic treatment (ST) alone.

Methods: 73 hand dactylitis were assessed in a prospective observational study by the Leeds Dactylitis Index basic (LDI-b) score and evaluated for pain (VAS pain), functional impairment (VAS-FI). In accordance with EULAR and GRAPPA recommendations, steroid injection was proposed to all patients. Patients who refused LT were treated with oral NSAIDs. The patients of the two groups continued baseline therapy with csDMARDs or corticosteroids. The clinical outcomes were measured at baseline, 1 month (T1) and 3 months (T3) by assessors blinded to this study.

Results: The reduction of VAS-pain, VAS-FI and LDI-b values was statistically significant higher in the LT group as compared to the ST group, both at T1 (p <0.001, p<0.001 and p=0.008, respectively) and at T3 (p<0.001, p<0.001 and p<0.001, respectively) (see Table 1). A clinically meaningful treatment response was observed at T1 in 33 (87%) digits in LT group and in 6 (17%) digits in ST group (p < 0.001). At T3, clinical response improved significantly in both the groups, with significant difference (see Table 2). In both the groups, no local and systemic adverse events were observed during the follow up period.

Table 2. Percentage of Significant response and Remission of dactylitis.

		T1 1 month	T3 3 months
Significant response, n (%)	LT	33 (86.8%)	36 (94.7%)
	ST	6 (17.1%)	11 (31.4%)
	p value	< 0.001	< 0.001
Remission n (%)	LT	1 (2.8%)	7 (18.4%)
	ST	0 (0%)	0 (0%)
	p value	ns	0.012

Values are presented as number of dactylitic fingers achieving response/remission. p values < 0.05 were considered statistically significant.

Conclusion: For the first time, we show the effectiveness of steroid injection into the digital flexor tendon sheath in improving clinical aspects and symptoms of hand psoriatic dactylitis.

References:

- [1] Gladman DD, Ziouza O, Thavaneswaran A, Chandran V. Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era. *J Rheumatol*. 2013;40:1357-9.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.6036

THU0373

SECUKINUMAB DOSE ESCALATION ON ACR RESPONSES IN ANTI-TUMOUR NECROSIS FACTOR NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS: 2-YEAR DATA FROM THE PHASE 3 FUTURE 4 AND FUTURE 5 STUDIES

P. Emery¹, M. Østergaard², L. C. Coates³, A. Deodhar⁴, E. Quebe-Fehling⁵, P. Pellet⁶, L. Pricop⁶, C. Gaillez⁵, F. Van den Bosch^{7,8}. ¹University of Leeds, Leeds, United Kingdom; ²Copenhagen University, København, Denmark; ³University of Oxford, Oxford, United Kingdom; ⁴Oregon Health & Science University, Portland, United States of America; ⁵Novartis Pharma AG, Basel, Switzerland; ⁶Novartis Pharmaceuticals Corp., East Hanover, United States of America; ⁷Ghent University Hospital, Ghent, Belgium; ⁸VIB Inflammation Research Centre, Ghent University, Ghent, Belgium

Background: Secukinumab (SEC) 150 and 300 mg doses are approved for the treatment of psoriatic arthritis (PsA). SEC 300 mg is the recommended dose for patients (pts) with concomitant moderate-to-severe plaque psoriasis or who are anti-tumour necrosis factor (TNF) inadequate responders. An increase from